Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Atripla in Virologically Suppressed HIV-1
NCT00365612Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2006
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of tenofovir disoproxil fumarate in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion of patients with HIV-1 RNA levels <200 copies/mL at 48 weeks. Started Jul 2006; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00365612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00365612.